Literature DB >> 15003429

Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D).

Stephen R Wisniewski1, Diane Stegman, Madhukar Trivedi, Mustafa M Husain, Heather Eng, Kathy Shores-Wilson, James Luther, Melanie M Biggs, Diane Burroughs, A Louise Ritz, Maurizio Fava, Frederic Quitkin, A John Rush.   

Abstract

In large multi-site trials, a feasibility or pilot study can be crucial to test the functionality of all aspects of conducting the study prior to the initiation of the formal study. A feasibility trial was conducted for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Project, a multi-site, prospective, sequentially randomized, clinical trial of outpatients with nonpsychotic major depressive disorder. From 14 December 2000 to 8 June 2001, 42 patients were screened for enrollment into the STAR*D Feasibility Trial. Twenty-four patients who were eligible and consented to participate were treated with citalopram for up to 12 weeks. During the course of this trial, issues were raised that resulted in modifications to the study procedures. Modifications made as a result of this trial affected four domains: (1) communication, (2) patient and provider burden, (3) data collection forms, and (4) recruitment and retention of subjects. This paper describes what was learned during the STAR*D Feasibility Trial so researchers planning to conduct similar trials can learn the practical issues related to conducting such a research project. While the information gathered was useful, it did delay the initiation of the formal trial. We view this cost as an investment in the development of overall study procedures that should lead to a stronger study.

Entities:  

Mesh:

Year:  2004        PMID: 15003429     DOI: 10.1016/j.jpsychires.2003.06.001

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  2 in total

1.  Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.

Authors:  David A Mrazek; Joanna M Biernacka; Donald E McAlpine; Joachim Benitez; Victor M Karpyak; Mark D Williams; Daniel K Hall-Flavin; Pamela J Netzel; Victoria Passov; Barbara M Rohland; Gen Shinozaki; Astrid A Hoberg; Karen A Snyder; Maureen S Drews; Michelle K Skime; Jessica A Sagen; Daniel J Schaid; Richard Weinshilboum; David J Katzelnick
Journal:  J Clin Psychopharmacol       Date:  2014-06       Impact factor: 3.153

2.  The first 100 patients in the SUN(^_^)D trial (strategic use of new generation antidepressants for depression): examination of feasibility and adherence during the pilot phase.

Authors:  Shinji Shimodera; Tadashi Kato; Hirotoshi Sato; Kazuhira Miki; Yoshihiro Shinagawa; Masaki Kondo; Hirokazu Fujita; Ippei Morokuma; Yoshio Ikeda; Tatsuo Akechi; Norio Watanabe; Mitsuhiko Yamada; Masatoshi Inagaki; Naohiro Yonemoto; Toshi A Furukawa
Journal:  Trials       Date:  2012-06-08       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.